KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Non-Current Assets (2018 - 2025)

Vir Biotechnology's Non-Current Assets history spans 8 years, with the latest figure at $488.7 million for Q4 2025.

  • For Q4 2025, Non-Current Assets rose 37.15% year-over-year to $488.7 million; the TTM value through Dec 2025 reached $1.8 billion, down 3.1%, while the annual FY2025 figure was $488.7 million, 37.15% up from the prior year.
  • Non-Current Assets for Q4 2025 was $488.7 million at Vir Biotechnology, up from $473.8 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $580.9 million in Q1 2024 and bottomed at $142.5 million in Q1 2021.
  • The 5-year median for Non-Current Assets is $330.8 million (2022), against an average of $347.4 million.
  • The largest annual shift saw Non-Current Assets surged 167.39% in 2021 before it tumbled 35.35% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $391.4 million in 2021, then fell by 27.7% to $283.0 million in 2022, then rose by 16.9% to $330.8 million in 2023, then grew by 7.71% to $356.4 million in 2024, then skyrocketed by 37.15% to $488.7 million in 2025.
  • Per Business Quant, the three most recent readings for VIR's Non-Current Assets are $488.7 million (Q4 2025), $473.8 million (Q3 2025), and $456.8 million (Q2 2025).